Granules India's subsidiary, Granules Pharmaceuticals Inc, has received approval from the USFDA for its generic version of ...

Granules India has received U.S. Food and Drug Administration approval for Lisdexamfetamine Dimesylate chewable tablets, its generic version of Takeda Pharmaceuticals’ central nervous system ...

Granules India Limited, a vertically integrated Indian pharmaceutical company, announced that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received approval from the ...

The report "Nucleating & Clarifying Agents Market by Agent Type (Nucleators, Clarifiers), Form (Powder, Granules, Liquid), ...

Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable ...

Drug maker Granules India Ltd. announced on Tuesday that its subsidiary, Granules Pharmaceuticals Inc., has received approval from the US Food and Drug Administration for a generic version of a ...

Granules India is primarily involved in the manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). Granules ...

Granules India Ltd has received approval from the United States Food and Drug Administration (USFDA) for Lisdexamfetamine Dimesylate chewable tablets, used in the treatment of Attention Deficit ...

Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received ...

Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable ...